ReP USP - Resultado da busca

Artigo de periodico
SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer (2017)
Soria, J. C.; Fülöp, A. ; Maciel, Carlos Dias ; Fischer, J. R.; Girotto, G.; Lago, S; Smith, E; Ostoros, G.; Eberhardt, W. E. E.; Lishkovska, P; Lovick, S.; Mariani, G.; McKeown, A; Kilgour, E; Smith, P; Bowen. K; Kohlmann, A; Carlile, D. J.; Jänne. P. A.
Fonte: Annals of Oncology. Unidade: EESC
Assuntos: ONCOLOGIA, NEOPLASIAS PULMONARES, METÁSTASE NEOPLÁSICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SORIA, J. C. et al. SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer. Annals of Oncology, v. 28, n. 12, p. 3028-3036, 2017Tradução . . Disponível em: http://dx.doi.org/10.1093/annonc/mdx628. Acesso em: 27 ago. 2024.
APA
Soria, J. C., Fülöp, A., Maciel, C. D., Fischer, J. R., Girotto, G., Lago, S., et al. (2017). SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer. Annals of Oncology, 28( 12), 3028-3036. doi:10.1093/annonc/mdx628
NLM
Soria JC, Fülöp A, Maciel CD, Fischer JR, Girotto G, Lago S, Smith E, Ostoros G, Eberhardt WEE, Lishkovska P, Lovick S, Mariani G, McKeown A, Kilgour E, Smith P, Bowen. K, Kohlmann A, Carlile DJ, Jänne. P. A. SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer [Internet]. Annals of Oncology. 2017 ; 28( 12): 3028-3036.[citado 2024 ago. 27 ] Available from: http://dx.doi.org/10.1093/annonc/mdx628
Vancouver
Soria JC, Fülöp A, Maciel CD, Fischer JR, Girotto G, Lago S, Smith E, Ostoros G, Eberhardt WEE, Lishkovska P, Lovick S, Mariani G, McKeown A, Kilgour E, Smith P, Bowen. K, Kohlmann A, Carlile DJ, Jänne. P. A. SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer [Internet]. Annals of Oncology. 2017 ; 28( 12): 3028-3036.[citado 2024 ago. 27 ] Available from: http://dx.doi.org/10.1093/annonc/mdx628
Artigo de periodico
The role of oral hygiene in head and neck cancer: results from International Head and Neck Cancer Epidemiology (INHANCE) consortium (2016)
Hashim, Dana ; Divaris, Kimon ; Wünsch-Filho, Victor ; Brennan, Paul J. ; Sartori, Samantha ; Curado, Maria Paula ; Olshan, Andrew F. ; Zevallos, Jose; Winn, Deborah M. ; Franceschi, Silvia ; Castellsagué, Xavier ; Lissowska, Jolanta ; Rudnai, Péter; Matsuo, Keitaro ; Morgenstern, Harold M.; Chen, Chu ; Vaughan, Thomas Leonard ; Hofmann, Jonathan N. ; Boffetta, Paolo
Fonte: Annals of Oncology. Unidade: FSP
Assuntos: NEOPLASIAS DE CABEÇA E PESCOÇO, NEOPLASIAS OROFARÍNGEAS, HIGIENE BUCAL, NEOPLASIAS FARÍNGEAS, NEOPLASIAS BUCAIS, ANÁLISE DE CONGLOMERADOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
HASHIM, Dana et al. The role of oral hygiene in head and neck cancer: results from International Head and Neck Cancer Epidemiology (INHANCE) consortium. Annals of Oncology, v. 27, n. 8, p. 1619-1625, 2016Tradução . . Disponível em: https://doi.org/10.1093/annonc/mdw224. Acesso em: 27 ago. 2024.
APA
Hashim, D., Divaris, K., Wünsch-Filho, V., Brennan, P. J., Sartori, S., Curado, M. P., et al. (2016). The role of oral hygiene in head and neck cancer: results from International Head and Neck Cancer Epidemiology (INHANCE) consortium. Annals of Oncology, 27( 8), 1619-1625. doi:10.1093/annonc/mdw224
NLM
Hashim D, Divaris K, Wünsch-Filho V, Brennan PJ, Sartori S, Curado MP, Olshan AF, Zevallos J, Winn DM, Franceschi S, Castellsagué X, Lissowska J, Rudnai P, Matsuo K, Morgenstern HM, Chen C, Vaughan TL, Hofmann JN, Boffetta P. The role of oral hygiene in head and neck cancer: results from International Head and Neck Cancer Epidemiology (INHANCE) consortium [Internet]. Annals of Oncology. 2016 ;27( 8): 1619-1625.[citado 2024 ago. 27 ] Available from: https://doi.org/10.1093/annonc/mdw224
Vancouver
Hashim D, Divaris K, Wünsch-Filho V, Brennan PJ, Sartori S, Curado MP, Olshan AF, Zevallos J, Winn DM, Franceschi S, Castellsagué X, Lissowska J, Rudnai P, Matsuo K, Morgenstern HM, Chen C, Vaughan TL, Hofmann JN, Boffetta P. The role of oral hygiene in head and neck cancer: results from International Head and Neck Cancer Epidemiology (INHANCE) consortium [Internet]. Annals of Oncology. 2016 ;27( 8): 1619-1625.[citado 2024 ago. 27 ] Available from: https://doi.org/10.1093/annonc/mdw224
Artigo de periodico
Florence: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk (2015)
Spina, M.; Nagy, Z.; Ribera, J. M.; Federico, M.; Aurer, I.; Jordan, K.; Borsaru, G.; Pristupa, A. S.; Bosi, A.; Grosicki, S.; Glushko, N. L.; Ristic, D.; Jakucs, J.; Montesinos, P.; Mayer, J.; Rego, Eduardo Magalhães; Baldini, S.; Scartoni, S.; Capriati, A.; Maggi, C. A.; Simonelli, C.
Fonte: Annals of Oncology. Unidade: FMRP
Assuntos: NEOPLASIAS, HEMATOLOGIA, RIM, ÁCIDO ÚRICO, DOENÇAS HEMATOLÓGICAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SPINA, M. et al. Florence: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. Annals of Oncology, v. 26, n. 10, p. 2155-2161, 2015Tradução . . Disponível em: https://doi.org/10.1093/annonc/mdv317. Acesso em: 27 ago. 2024.
APA
Spina, M., Nagy, Z., Ribera, J. M., Federico, M., Aurer, I., Jordan, K., et al. (2015). Florence: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. Annals of Oncology, 26( 10), 2155-2161. doi:10.1093/annonc/mdv317
NLM
Spina M, Nagy Z, Ribera JM, Federico M, Aurer I, Jordan K, Borsaru G, Pristupa AS, Bosi A, Grosicki S, Glushko NL, Ristic D, Jakucs J, Montesinos P, Mayer J, Rego EM, Baldini S, Scartoni S, Capriati A, Maggi CA, Simonelli C. Florence: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk [Internet]. Annals of Oncology. 2015 ; 26( 10): 2155-2161.[citado 2024 ago. 27 ] Available from: https://doi.org/10.1093/annonc/mdv317
Vancouver
Spina M, Nagy Z, Ribera JM, Federico M, Aurer I, Jordan K, Borsaru G, Pristupa AS, Bosi A, Grosicki S, Glushko NL, Ristic D, Jakucs J, Montesinos P, Mayer J, Rego EM, Baldini S, Scartoni S, Capriati A, Maggi CA, Simonelli C. Florence: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk [Internet]. Annals of Oncology. 2015 ; 26( 10): 2155-2161.[citado 2024 ago. 27 ] Available from: https://doi.org/10.1093/annonc/mdv317

Unidades USP

ReP

Filtros

Autores

Assuntos

Indexado em

Afiliação dos autores externos não normalizada

País das instituições de afiliação dos autores externos